+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2023-2030- Product Image
Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2023-2030- Product Image
Sale

Global Next-Generation Cancer Diagnostics Market by Technology, Cancer Type, Application, Function - Forecast 2023-2030

  • PDF Icon

    Report

  • 185 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5311174
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Next-Generation Cancer Diagnostics Market size was estimated at USD 7.96 billion in 2022, USD 9.77 billion in 2023, and is expected to grow at a CAGR of 23.93% to reach USD 44.36 billion by 2030.

Increasing diagnostic numbers have led clinicians and scientists to work to find solutions for patients afflicted with cancer. Next-generation cancer diagnostics has emerged as advanced technologies to detect slow-growing primary tumors and biomarkers at early stages and assure better treatment. Government initiatives to expand large-scale cancer screening activities and the growing use of microfluidic chips in cancer treatment have paved the way for better adoption of next-generation cancer technologies. However, concerns associated with limited standardization of diagnostics and the risks associated with their use significantly impede product adoption across hospitals & clinics. Market players are investing in new technology advancements for next-generation sequencing, along with improving the diagnostics to enhance personalized medicine treatment is expected to drive the R&D in next-generation cancer diagnostics. Clinicians and translational researchers are expected to engage in direct dialog, both within and across institutions, to rise the integration of genomic data and clinical phenotypes and enable precision cancer medicine through next-generation cancer diagnostics approaches.

Regional Insights

The Americas next-generation cancer diagnostics market portrays a large number of regional players with a strong technological foothold in developing oncology diagnostics. Healthcare regulatory bodies in the U.S. and Canada have observed a prominent rise in the number of approvals provided for next-generation cancer diagnostics. Increasing R&D activities to develop technologically advanced cancer screening tests and the growing establishment of cancer diagnostic facilities are accelerating the market development in the Asia-Pacific.  The next-generation sequencing test is accepted as part of standard cancer care and is being reimbursed in several Western and Asian nations. Europe observes an elevating number of cancer screening programs across the EU and the UK. Moreover, European and American market players aim to serve cancer treatment centers in the Middle East by expanding their ??international distribution links and entering new territories, including Saudi Arabia, Lebanon, Egypt, and Pakistan.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Agena Bioscience, Inc. by Mesa Laboratories, Inc., Agilent Technologies, Inc., Akadeum Life Sciences, Almac Group, Becton, Dickinson & Company, Bio-Techne Corporation, Biological Dynamics Inc., bioMérieux SA, BioNTech SE, Castle Biosciences Inc., Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare, Hologic Inc., Illumina, Inc., Johnson & Johnson Services, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., NeoGenomics Laboratories, Novartis AG, OPKO Health, Inc., Oxford Nanopore Technologies Limited, Perkin Elmer, Inc., Qiagen N.V., Siemens Healthineers AG, Sysmex Corporation, Telerad Tech, and Thermo Fisher Scientific, Inc.

Market Segmentation & Coverage

This research report categorizes the Next-Generation Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Technology
    • Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
    • DNA Microarrays
    • Lab-on-a-Chip & Reverse Transcriptase-PCR
    • Molecular Diagnostics
    • Next Generation Sequencing
    • Protein Microarrays
    • qPCR & Multiplexing
  • Cancer Type
    • Bladder Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Thyroid Cancer
    • Uterine Cancer
  • Application
    • Cancer Screening
    • Companion Diagnostics
    • Prognostics
    • Risk Analysis
    • Therapeutic Monitoring
  • Function
    • Biomarker Development
    • CTC Analysis
    • Epigenetic Analysis
    • Genetic Analysis
    • Proteomic Analysis
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Next-Generation Cancer Diagnostics Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Cancer Diagnostics Market?
  3. What are the technology trends and regulatory frameworks in the Next-Generation Cancer Diagnostics Market?
  4. What is the market share of the leading vendors in the Next-Generation Cancer Diagnostics Market?
  5. Which modes and strategic moves are suitable for entering the Next-Generation Cancer Diagnostics Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Next-Generation Cancer Diagnostics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Burden of Cancer Cases Globally and Need for Efficient Diagnostics
5.1.1.2. Growing Utilization of Microfluidic Chips in Cancer Management
5.1.1.3. Government Initiatives Towards Cancer Screening
5.1.2. Restraints
5.1.2.1. High Investment and Insufficient Standardization of Diagnostics
5.1.3. Opportunities
5.1.3.1. Proliferation of Personalized and Advanced Genome Medicine
5.1.3.2. Technological Advancements in Next-Generation Cancer Diagnostics
5.1.4. Challenges
5.1.4.1. Limitations and Risks Associated with NGC Diagnostics
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Next-Generation Cancer Diagnostics Market, by Technology
6.1. Introduction
6.2. Clustered Regularly Interspaced Short Palindromic Repeats Diagnostics
6.3. DNA Microarrays
6.4. Lab-on-a-Chip & Reverse Transcriptase-PCR
6.5. Molecular Diagnostics
6.6. Next Generation Sequencing
6.7. Protein Microarrays
6.8. qPCR & Multiplexing
7. Next-Generation Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. Bladder Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Lung Cancer
7.8. Pancreatic Cancer
7.9. Prostate Cancer
7.10. Thyroid Cancer
7.11. Uterine Cancer
8. Next-Generation Cancer Diagnostics Market, by Application
8.1. Introduction
8.2. Cancer Screening
8.3. Companion Diagnostics
8.4. Prognostics
8.5. Risk Analysis
8.6. Therapeutic Monitoring
9. Next-Generation Cancer Diagnostics Market, by Function
9.1. Introduction
9.2. Biomarker Development
9.3. CTC Analysis
9.4. Epigenetic Analysis
9.5. Genetic Analysis
9.6. Proteomic Analysis
10. Americas Next-Generation Cancer Diagnostics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Next-Generation Cancer Diagnostics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Next-Generation Cancer Diagnostics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Adaptive Biotechnologies Corporation
14.1.3. Agena Bioscience, Inc. by Mesa Laboratories, Inc.
14.1.4. Agilent Technologies, Inc.
14.1.5. Akadeum Life Sciences
14.1.6. Almac Group
14.1.7. Becton, Dickinson & Company
14.1.8. Bio-Techne Corporation
14.1.9. Biological Dynamics Inc.
14.1.10. bioMérieux SA
14.1.11. BioNTech SE
14.1.12. Castle Biosciences Inc.
14.1.13. Danaher Corporation
14.1.14. Exact Sciences Corporation
14.1.15. F. Hoffmann-La Roche Ltd.
14.1.16. GE HealthCare
14.1.17. Hologic Inc.
14.1.18. Illumina, Inc.
14.1.19. Johnson & Johnson Services, Inc.
14.1.20. Konica Minolta, Inc.
14.1.21. Koninklijke Philips N.V.
14.1.22. NeoGenomics Laboratories
14.1.23. Novartis AG
14.1.24. OPKO Health, Inc.
14.1.25. Oxford Nanopore Technologies Limited
14.1.26. Perkin Elmer, Inc.
14.1.27. Qiagen N.V.
14.1.28. Siemens Healthineers AG
14.1.29. Sysmex Corporation
14.1.30. Telerad Tech
14.1.31. Thermo Fisher Scientific, Inc.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 2. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 7. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2030 (%)
FIGURE 8. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2030 (%)
FIGURE 10. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 12. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
FIGURE 14. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
List of Tables
TABLE 1. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 6. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 14. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THYROID CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 31. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY BIOMARKER DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CTC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY EPIGENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY GENETIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY PROTEOMIC ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 49. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 50. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 51. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 53. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 54. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 71. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 75. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 76. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 77. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 78. INDIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 83. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 84. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 85. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 86. JAPAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 95. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 99. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 103. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 104. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 105. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 107. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 109. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. THAILAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 111. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 113. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. VIETNAM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 120. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 122. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 123. DENMARK NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 124. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 125. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 126. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. EGYPT NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 128. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 130. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. FINLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 132. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 134. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 135. FRANCE NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 136. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 137. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 138. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. GERMANY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 140. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 142. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. ISRAEL NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 144. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 146. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. ITALY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 148. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 152. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 153. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 154. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. NIGERIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 156. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 158. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 159. NORWAY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 160. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 162. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. POLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 164. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 165. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 166. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. QATAR NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 180. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 181. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 182. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SPAIN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 184. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 186. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. SWEDEN NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 188. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 189. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 190. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. SWITZERLAND NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 192. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 193. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 194. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 195. TURKEY NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM NEXT-GENERATION CANCER DIAGNOSTICS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 204. NEXT-GENERATION CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 205. NEXT-GENERATION CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 206. NEXT-GENERATION CANCER DIAGNOSTICS MARKET LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agena Bioscience, Inc. by Mesa Laboratories, Inc.
  • Agilent Technologies, Inc.
  • Akadeum Life Sciences
  • Almac Group
  • Becton, Dickinson & Company
  • Bio-Techne Corporation
  • Biological Dynamics Inc.
  • bioMérieux SA
  • BioNTech SE
  • Castle Biosciences Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips N.V.
  • NeoGenomics Laboratories
  • Novartis AG
  • OPKO Health, Inc.
  • Oxford Nanopore Technologies Limited
  • Perkin Elmer, Inc.
  • Qiagen N.V.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Telerad Tech
  • Thermo Fisher Scientific, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMarch 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 9.77 Billion
Forecasted Market Value ( USD ) by 2030 $ 44.36 Billion
Compound Annual Growth Rate23.9%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (LOAC & RT-PCR, Protein Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Next Generation Cancer Diagnostics Market Size, Share & Trends Analysis Report By Technology (LOAC & RT-PCR, Protein Microarrays), By Application, By Cancer Type, By Function, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 236 Pages
  • Global
From
Global Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Forecast 2024-2030 - Product Image

Global Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Forecast 2024-2030

  • Report
  • 192 Pages
  • Global
From
Global Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Forecast 2024-2030 - Product Image

Global Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Forecast 2024-2030

  • Report
  • 181 Pages
  • Global
From
Next Generation Cancer Diagnostics - Global Strategic Business Report - Product Image

Next Generation Cancer Diagnostics - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Platform-based, Instrument-based), By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 190 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.